A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia

Leukemia

Volumn 29, Issue 5, 2015, Pages 1069-1075

  Piemontese, S ^a,b   Ciceri, F ^a,b   Labopin, M ^b,c,d   Bacigalupo, A ^e   Huang, H ^f   Santarone, S ^g   Gorin, N C ^b,c,d   Koc, Y ^h   Wu, D ⁱ   Beelen, D ^j   Tischer, J ^k   Ehninger, G ^l   Arcese, W ^m   Nagler, A ^b,n   Mohty, M ^b,c,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e UNIVERSITY OF GENOA   (Italy)

^f ZHEJIANG UNIVERSITY   (China)

^g Ospedale Civile   (Italy)

^h MEDICAL PARK HOSPITAL   (Turkey)

ⁱ THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^m TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

ⁿ SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; VEIN OCCLUSION; ADOLESCENT; ALLELE; ALLOTRANSPLANTATION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; METABOLISM; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RECURRENT DISEASE; REMISSION; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME; YOUNG ADULT;

MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929288353     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.336     Document Type: Article

References (42)

1. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30: 4515-4523.
2. Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant 2011; 46: 323-329.
3. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-771.
4. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
5. O' Reilly RJ, Kernan NA, Cunningham I. Allogeneic transplants depleted of T cells by soybean lectin agglutination and E-rosette depletion. Bone Marrow Transplant 1988; 3: 3-6.
6. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell depleted haploidentical three loci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
7. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
8. Aversa F, Terenzi A, Carotti A, Felicini R, Jacucci R, Zei T et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol 1999; 17: 1545-1550.
9. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574-3581.
10. Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y et al. Haploidentical 'megadose' stem cell transplantation in acute leukaemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings. Leukemia 2002; 16: 427-428.
11. Waller EK, Giver CR, Rosenthal H, Somani J, Langston AA, Lonial S et al. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis 2004; 33: 233-237.
12. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotypemismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukaemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
13. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical stem-cell transplantation for leukemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
14. Ji SQ, Chen HR, Wang HX, Yan HM, Zhu L, Liu J et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30: 861-866.
15. Lee KH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex-vivo T-cell depletion after reduced-intensity conditioning with busulfan, fludarabine and antithymocyte globulin. Biol Blood Marrow Transplant 2009; 15: 61-72.
16. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073.
17. Luznik L, O' Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650.
18. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood and Marrow Transplant 2013; 19: 117-122.
19. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849-857.
20. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MTL et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2015; 29: 396-405.
21. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on AGvHD grading. Bone Marrow Transplant 1995; 15: 825-828.
22. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
25. Mantel N. Evaluation of survival data and two new rank order statitics arising in its consideration. Cancer Chemother Rep 1996; 503: 163-170.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
27. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
28. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
29. Rowe JM. Prognostic factors in adult acute lymphoblastic leukemia. Br J Haematol 2010; 150: 389-405.
30. Ringdén O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-4577.
31. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012; 119: 3908-3916.
32. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical sibling. J Clin Oncol 1997; 15: 1767-1777.
33. Gorin NC, Labopin M, Rocha V, Arcese W, Beksac M, Gluckman E et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocitic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102: 3043-3051.
34. Flower ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW et al. Comparative analysis of risk factors for acute graft-versus-host disease Institutes of Health consensus criteria and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214-3219.
35. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119: 296-307.
36. Luznik L, O'Donnel PV, Fuchs JE. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT. Semin Oncol 2012; 39: 1-16.
37. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690-697.
38. van Rood JJ, Loberiza FR Jr, Zhang MJ, Oudshoorn M, Claas F, Cairo MS et al. Effect of tolerance to non-inherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002; 99: 1572-1577.
39. Wang Y, Chang Y-J, Xu L-P, Liu K-Y, Liu D-H, Zhang X-H et al. Who is the best donor for a related HLA-haplotype-mismatched transplant? Blood 2014; 124: 843-850.
40. Wang Y, Liu D-H, Liu K-Y, Xu L-P, Zhang X-H, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer 2013; 119 : 978-985.
41. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J et al. Nonmyeloablative HLA-haploidentical BMT with high-dose postransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16: 482-489.
42. Brunstein CG, Fuchs EJ, Carter SJ, Karanes C, Costa LJ, Wu J et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282-288.